Cary Pharmaceuticals is focused on developing innovative pharmaceutical solutions, particularly in the areas of smoking cessation and catheter care. One of their key products is QuitPak®, a patented treatment designed to assist individuals in quitting smoking. This product reflects the company's commitment to addressing public health challenges through effective therapeutic options. Additionally, Cary Pharmaceuticals is working on a novel catheter lock solution aimed at preventing clot formation in catheters, which is crucial for improving patient safety and outcomes in medical settings.

The company is guided by a seasoned management team with extensive experience in the pharmaceutical industry. This includes leadership from Douglas Cary, who has a background with Abbott Laboratories, and Carl Schwan, who has successfully managed initial public offerings. The involvement of Lester Crawford, a former Commissioner of the U.S. Food and Drug Administration (FDA), further underscores the company's dedication to regulatory compliance and the development of safe, effective medical products. Through these initiatives, Cary Pharmaceuticals aims to make significant contributions to healthcare and improve the quality of life for patients.

United States

Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of QuitPak®, a patented treatment for smoking cessation, and a novel catheter lock solution to prevent clot formation in catheters. The Company is led by an experienced management team and Board of Directors, including Douglas Cary (President) a former Abbott Laboratories executing; Carl Schwan (CFO) a former CFO for two successful initial public offerings that raised $80 million; and Lester Crawford (Director), Former Commissioner of the U.S. Food and Drug Admininstration (FDA).

Cary Pharmaceuticals

Company Details